Verastem Newsroom

Verastem Is Maintained at Outperform by Mizuho

Dow JonesDec 19 09:10 ET

Verastem Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow JonesDec 19 07:18 ET

Verastem Analyst Ratings

BenzingaDec 19 07:08 ET

Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $9

Moomoo NewsDec 18 07:34 ET

BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13

Moomoo NewsDec 16 20:31 ET

Verastem's Promising Drug Combination for LGSOC: Analyst Recommends Buy Rating

TipRanksDec 16 19:53 ET

RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13

Moomoo NewsNov 7 07:31 ET

A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14

Moomoo NewsNov 7 07:31 ET

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsNov 7 06:31 ET

Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating

TipRanksNov 4 06:48 ET

Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib

TipRanksOct 21 08:50 ET

Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 19 05:32 ET

Verastem Price Target Maintained With a $13.00/Share by RBC Capital

Dow JonesOct 18 10:02 ET

Verastem Analyst Ratings

BenzingaOct 18 07:21 ET

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsOct 18 06:31 ET

Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 17 14:32 ET

Truist Remains Bullish on Verastem, Says Weakness in Shares 'an Overreaction'

TipRanksOct 17 14:07 ET

Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential

TipRanksOct 17 14:07 ET

Verastem Analyst Ratings

BenzingaSep 30 07:09 ET

Guggenheim Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $13

Moomoo NewsSep 30 06:33 ET